Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial

Karsten Gjessing Jensen; Stefan Gärtner; Christoph U. Correll; Ditte Rudå; Dea Gowers Klauber; Marie Stentebjerg-Olesen; Birgitte Fagerlund; Jens Richardt Jepsen; Anders Fink-Jensen; Klaus Juul; Anne Katrine Pagsberg

doi:10.1007/s00213-017-4784-5

Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial

Karsten Gjessing Jensen, Stefan Gärtner, Christoph U. Correll, Ditte Rudå, Dea Gowers Klauber, Marie Stentebjerg-Olesen, Birgitte Fagerlund, Jens Richardt Jepsen, Anders Fink-Jensen, Klaus Juul, Anne Katrine Pagsberg^*

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

2 Citationer (Scopus)

Abstract

Objective: The aim of this study was to compare the effect of quetiapine extended release (ER) versus aripiprazole on corrected QT interval (QTc) and QT dispersion (QTd) in youths with first-episode psychosis. Methods: Youths 12–17 years were randomized to quetiapine ER (daily dose range = 50 to 800 mg) or aripiprazole (daily dose range = 2.5 to 30 mg) in a 12-week double-blinded trial and examined at weeks 0, 4, and 12. Primary outcome was QTc change using Hodges formula (QTcH); secondary outcomes included QTcH > 450 ms, QTcH > 500 ms, QTcH change > 60 ms, QTd, and heart rate (HR). Results: Among 113 randomized youths, follow-up ECG was available for 93 patients (82.3%) (age = 15.8 ± 1.3 years, males = 34.4%, schizophrenia = 67.7%). Quetiapine ER treatment (n = 47) was associated with a significant increase in QTcH of + 6.8 ± 20.2 ms (p = 0.025), while the change from baseline in patients receiving aripiprazole (n = 46) was non-significant (− 3.4 ± 18.9 ms, p = 0.225). One patient in the quetiapine ER group had a QTcH change of + 62.3 ms. Age, sex, smoking, body mass index, and concomitant medication were not significantly associated with QTcH change, but higher baseline potassium was correlated to higher QTcH change in the quetiapine ER group. The HR increased significantly with quetiapine ER (+ 11.0 ± 14.2 bpm, p < 0.001) but not with aripiprazole (− 0.8 ± 12.0 bpm, p = 0.643). QTd did not significantly change with quetiapine ER or aripiprazole. Conclusion: QTcH and HR increased significantly with quetiapine ER, although changes were small and likely not clinically significant in otherwise healthy patients. QTcH and HR were unchanged with aripiprazole. No significant change in QTd was seen. ClinicalTrials.gov: NCT01119014, EudraCT: 2009-016715-38

Originalsprog	Engelsk
Tidsskrift	Psychopharmacology
Vol/bind	235
Udgave nummer	3
Sider (fra-til)	681–693
ISSN	0033-3158
DOI	https://doi.org/10.1007/s00213-017-4784-5
Status	Udgivet - 1 mar. 2018

Adgang til dokumentet

10.1007/s00213-017-4784-5

Citationsformater

Jensen, K. G., Gärtner, S., Correll, C. U., Rudå, D., Klauber, D. G., Stentebjerg-Olesen, M., Fagerlund, B., Jepsen, J. R., Fink-Jensen, A., Juul, K., & Pagsberg, A. K. (2018). Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. Psychopharmacology, 235(3), 681–693. https://doi.org/10.1007/s00213-017-4784-5

Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. / Jensen, Karsten Gjessing; Gärtner, Stefan; Correll, Christoph U. et al.
I: Psychopharmacology, Bind 235, Nr. 3, 01.03.2018, s. 681–693.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Jensen, KG, Gärtner, S, Correll, CU, Rudå, D, Klauber, DG, Stentebjerg-Olesen, M, Fagerlund, B, Jepsen, JR, Fink-Jensen, A, Juul, K & Pagsberg, AK 2018, 'Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial', Psychopharmacology, bind 235, nr. 3, s. 681–693. https://doi.org/10.1007/s00213-017-4784-5

@article{b53f65860a3b4e898135b356e48c631f,

title = "Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial",

abstract = "Objective: The aim of this study was to compare the effect of quetiapine extended release (ER) versus aripiprazole on corrected QT interval (QTc) and QT dispersion (QTd) in youths with first-episode psychosis. Methods: Youths 12–17 years were randomized to quetiapine ER (daily dose range = 50 to 800 mg) or aripiprazole (daily dose range = 2.5 to 30 mg) in a 12-week double-blinded trial and examined at weeks 0, 4, and 12. Primary outcome was QTc change using Hodges formula (QTcH); secondary outcomes included QTcH > 450 ms, QTcH > 500 ms, QTcH change > 60 ms, QTd, and heart rate (HR). Results: Among 113 randomized youths, follow-up ECG was available for 93 patients (82.3%) (age = 15.8 ± 1.3 years, males = 34.4%, schizophrenia = 67.7%). Quetiapine ER treatment (n = 47) was associated with a significant increase in QTcH of + 6.8 ± 20.2 ms (p = 0.025), while the change from baseline in patients receiving aripiprazole (n = 46) was non-significant (− 3.4 ± 18.9 ms, p = 0.225). One patient in the quetiapine ER group had a QTcH change of + 62.3 ms. Age, sex, smoking, body mass index, and concomitant medication were not significantly associated with QTcH change, but higher baseline potassium was correlated to higher QTcH change in the quetiapine ER group. The HR increased significantly with quetiapine ER (+ 11.0 ± 14.2 bpm, p < 0.001) but not with aripiprazole (− 0.8 ± 12.0 bpm, p = 0.643). QTd did not significantly change with quetiapine ER or aripiprazole. Conclusion: QTcH and HR increased significantly with quetiapine ER, although changes were small and likely not clinically significant in otherwise healthy patients. QTcH and HR were unchanged with aripiprazole. No significant change in QTd was seen. ClinicalTrials.gov: NCT01119014, EudraCT: 2009-016715-38",

keywords = "Adolescents, Antipsychotics, Children, Drug-related side effects and adverse reactions, ECG, Heart rate, QTc",

author = "Jensen, {Karsten Gjessing} and Stefan G{\"a}rtner and Correll, {Christoph U.} and Ditte Rud{\aa} and Klauber, {Dea Gowers} and Marie Stentebjerg-Olesen and Birgitte Fagerlund and Jepsen, {Jens Richardt} and Anders Fink-Jensen and Klaus Juul and Pagsberg, {Anne Katrine}",

year = "2018",

month = mar,

day = "1",

doi = "10.1007/s00213-017-4784-5",

language = "English",

volume = "235",

pages = "681–693",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis

T2 - results from the TEA trial

AU - Jensen, Karsten Gjessing

AU - Gärtner, Stefan

AU - Correll, Christoph U.

AU - Rudå, Ditte

AU - Klauber, Dea Gowers

AU - Stentebjerg-Olesen, Marie

AU - Fagerlund, Birgitte

AU - Jepsen, Jens Richardt

AU - Fink-Jensen, Anders

AU - Juul, Klaus

AU - Pagsberg, Anne Katrine

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: The aim of this study was to compare the effect of quetiapine extended release (ER) versus aripiprazole on corrected QT interval (QTc) and QT dispersion (QTd) in youths with first-episode psychosis. Methods: Youths 12–17 years were randomized to quetiapine ER (daily dose range = 50 to 800 mg) or aripiprazole (daily dose range = 2.5 to 30 mg) in a 12-week double-blinded trial and examined at weeks 0, 4, and 12. Primary outcome was QTc change using Hodges formula (QTcH); secondary outcomes included QTcH > 450 ms, QTcH > 500 ms, QTcH change > 60 ms, QTd, and heart rate (HR). Results: Among 113 randomized youths, follow-up ECG was available for 93 patients (82.3%) (age = 15.8 ± 1.3 years, males = 34.4%, schizophrenia = 67.7%). Quetiapine ER treatment (n = 47) was associated with a significant increase in QTcH of + 6.8 ± 20.2 ms (p = 0.025), while the change from baseline in patients receiving aripiprazole (n = 46) was non-significant (− 3.4 ± 18.9 ms, p = 0.225). One patient in the quetiapine ER group had a QTcH change of + 62.3 ms. Age, sex, smoking, body mass index, and concomitant medication were not significantly associated with QTcH change, but higher baseline potassium was correlated to higher QTcH change in the quetiapine ER group. The HR increased significantly with quetiapine ER (+ 11.0 ± 14.2 bpm, p < 0.001) but not with aripiprazole (− 0.8 ± 12.0 bpm, p = 0.643). QTd did not significantly change with quetiapine ER or aripiprazole. Conclusion: QTcH and HR increased significantly with quetiapine ER, although changes were small and likely not clinically significant in otherwise healthy patients. QTcH and HR were unchanged with aripiprazole. No significant change in QTd was seen. ClinicalTrials.gov: NCT01119014, EudraCT: 2009-016715-38

AB - Objective: The aim of this study was to compare the effect of quetiapine extended release (ER) versus aripiprazole on corrected QT interval (QTc) and QT dispersion (QTd) in youths with first-episode psychosis. Methods: Youths 12–17 years were randomized to quetiapine ER (daily dose range = 50 to 800 mg) or aripiprazole (daily dose range = 2.5 to 30 mg) in a 12-week double-blinded trial and examined at weeks 0, 4, and 12. Primary outcome was QTc change using Hodges formula (QTcH); secondary outcomes included QTcH > 450 ms, QTcH > 500 ms, QTcH change > 60 ms, QTd, and heart rate (HR). Results: Among 113 randomized youths, follow-up ECG was available for 93 patients (82.3%) (age = 15.8 ± 1.3 years, males = 34.4%, schizophrenia = 67.7%). Quetiapine ER treatment (n = 47) was associated with a significant increase in QTcH of + 6.8 ± 20.2 ms (p = 0.025), while the change from baseline in patients receiving aripiprazole (n = 46) was non-significant (− 3.4 ± 18.9 ms, p = 0.225). One patient in the quetiapine ER group had a QTcH change of + 62.3 ms. Age, sex, smoking, body mass index, and concomitant medication were not significantly associated with QTcH change, but higher baseline potassium was correlated to higher QTcH change in the quetiapine ER group. The HR increased significantly with quetiapine ER (+ 11.0 ± 14.2 bpm, p < 0.001) but not with aripiprazole (− 0.8 ± 12.0 bpm, p = 0.643). QTd did not significantly change with quetiapine ER or aripiprazole. Conclusion: QTcH and HR increased significantly with quetiapine ER, although changes were small and likely not clinically significant in otherwise healthy patients. QTcH and HR were unchanged with aripiprazole. No significant change in QTd was seen. ClinicalTrials.gov: NCT01119014, EudraCT: 2009-016715-38

KW - Adolescents

KW - Antipsychotics

KW - Children

KW - Drug-related side effects and adverse reactions

KW - ECG

KW - Heart rate

KW - QTc

U2 - 10.1007/s00213-017-4784-5

DO - 10.1007/s00213-017-4784-5

M3 - Journal article

C2 - 29185022

AN - SCOPUS:85035125250

SN - 0033-3158

VL - 235

SP - 681

EP - 693

JO - Psychopharmacology

JF - Psychopharmacology

IS - 3

ER -

Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater